Meningococcal group b vaccine - Biologic Drug Details

Summary for meningococcal group b vaccine

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for meningococcal group b vaccine

Recent Clinical Trials for meningococcal group b vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sanofi Pasteur, a Sanofi Company	PHASE1
Amgen	Phase 3
University of North Carolina, Chapel Hill	Phase 2

See all meningococcal group b vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for meningococcal group b vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for meningococcal group b vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	BEXSERO	meningococcal group b vaccine	Injection	125546		2021-01-17	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	BEXSERO	meningococcal group b vaccine	Injection	125546		2023-10-02	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	TRUMENBA	meningococcal group b vaccine	Injection	125549		2036-05-16	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	TRUMENBA	meningococcal group b vaccine	Injection	125549		2034-12-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for meningococcal group b vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	BEXSERO	meningococcal group b vaccine	Injection	125546		2035-11-13	Patent claims search
Glaxosmithkline Biologicals	BEXSERO	meningococcal group b vaccine	Injection	125546		2037-06-06	Patent claims search
Glaxosmithkline Biologicals	BEXSERO	meningococcal group b vaccine	Injection	125546		2034-04-23	Patent claims search
Wyeth Pharmaceuticals Llc	TRUMENBA	meningococcal group b vaccine	Injection	125549		2035-11-13	Patent claims search

International Patents for meningococcal group b vaccine

Country	Patent Number	Estimated Expiration
Canada	2770304
Australia	2014222308
Eurasian Patent Organization	201990091
European Patent Office	2461825

Meningococcal group b vaccine Market Analysis and Financial Projection

Last updated: February 17, 2026

Summary

The meningococcal group B vaccine market is characterized by steady growth driven by increasing disease awareness, expanding vaccine coverage, and evolving regulatory landscapes. Although the market faces challenges, including high development costs and competitive pressures, the financial trajectory remains positive, with global sales projected to grow at a compound annual growth rate (CAGR) of approximately 7% over the next five years.

What Are the Key Market Drivers for Meningococcal Group B Vaccines?

Disease Burden and Public Health Initiatives

Meningococcal B disease causes significant morbidity and mortality, particularly among infants, adolescents, and young adults. Public health agencies recommend vaccination for high-risk populations, increasing demand. Countries like the U.S., the U.K., and parts of Europe have integrated meningococcal B vaccines into routine immunization schedules.

Regulatory Approvals and Expanded Indications

The approval of vaccines such as Bexsero (GSK) and Trumenba (Pfizer) across multiple markets has facilitated broader adoption. Continued approval extensions, including additional age groups and booster doses, expand market potential.

Market Penetration and Pricing

High vaccine prices and subsidies influence revenue trajectories. Bexsero's list price in the U.S. ranges between $150 and $170 per dose, with three doses typically required. Government procurement programs and school-based initiatives drive volumes, impacting overall market size.

Competitive Landscape and Product Differentiation

Two primary vaccines dominate the market:

• Bexsero (GSK): Marketed globally with multiple dosing schedules and additional indications.
• Trumenba (Pfizer): Approved in the U.S. and EU, with a different dosing schedule and immunogenic profile.

Other entrants face barriers related to clinical trials, approval processes, and physician familiarity.

How Is the Market Structured?

Geographic Segmentation

• North America: Driven by high vaccine coverage, strong healthcare infrastructure, and widespread awareness.
• Europe: Adoption varies; some countries include meningococcal B vaccines in national immunization programs.
• Asia-Pacific: Emerging market with rising awareness; growth influenced by economic expansion and healthcare investment.
• Rest of the World: Limited penetration due to cost and infrastructure constraints.

Market Players and Their Strategies

• GSK and Pfizer control over 80% of global sales.
• Strategic alliances focus on licensing, vaccine development, and distribution expansion.
• Diversification into combination vaccines and booster doses targets increased revenue streams.

What Are the Financial Projections?

Revenue Estimates and Growth Trends

• The global meningococcal B vaccine market was valued at approximately $1.2 billion in 2022.
• Projected CAGR from 2023 to 2028: 7%, reaching roughly $1.9 billion by 2028.

Revenue Contributions by Region

Region	2022 Market Share	2028 Projected Share	CAGR (2023-2028)
North America	40%	42%	6.5%
Europe	33%	32%	6.8%
Asia-Pacific	15%	16%	10%
Rest of World	12%	10%	5.5%

Pricing and Payment Dynamics

Price sensitivity varies; high-income countries sustain higher prices driven by healthcare budgets, while lower-income countries depend on subsidies and Gavi funding. The price decline for vaccines is unlikely in the short term due to manufacturing costs and proprietary status.

Cost Considerations and R&D Investment

Development costs per vaccine range between $800 million and $1 billion, inclusive of clinical trials and regulatory compliance. Return on investment hinges on early market penetration and duration of patent exclusivity.

What Are the Challenges and Opportunities?

Challenges

• Rising competition from emerging vaccines and platform technologies.
• Variability in vaccination schedules and acceptance rates.
• Manufacturing complexities associated with conjugate vaccine production.
• Pricing pressures and reimbursement uncertainties in certain regions.

Opportunities

• Development of combination vaccines for broader protection.
• Expansion into high-risk and emerging markets.
• Optimizing dosing schedules and delivery methods to improve compliance and reduce costs.

Key Takeaways

• The meningococcal group B vaccine market is expanding with a CAGR of approximately 7% over five years.
• Leading players, GSK and Pfizer, dominate a consolidated market with significant growth potential.
• Geographic expansion into Asia and underserved regions offers lucrative opportunities.
• Pricing strategies and public health policies significantly influence market revenues.
• R&D investments focus on new formulations, combination vaccines, and broader indications.

FAQs

1. What factors influence the pricing of meningococcal B vaccines?
Pricing is driven by manufacturing costs, market demand, reimbursement policies, and regional healthcare budgets. High-income markets sustain premium prices, while lower-income regions rely on subsidies.

2. How does vaccine coverage impact market growth?
Higher coverage increases demand, especially in countries integrating meningococcal B vaccines into routine immunization programs. Low coverage limits market expansion.

3. What are the main regions contributing to market revenues?
North America and Europe lead, with Asia-Pacific expected to contribute increasingly due to rising healthcare investments and public awareness.

4. How do vaccine manufacturers differentiate their products?
Through dosing schedules, immunogenic profiles, approved indications, and delivery methods, such as combination vaccines.

5. What is the future outlook for novel meningococcal B vaccines?
Research focuses on longer-lasting immunity, broader serogroup coverage, and simplified dosing regimens, which could reshape the market dynamics and increase overall revenues.

Citations

1. IQVIA, "Global Vaccines Market Report," 2022.
2. GSK, "Bexsero Product Information," 2023.
3. Pfizer, "Trumenba Data Sheet," 2023.
4. World Health Organization, "Vaccine Market Profiles," 2022.
5. MarketsandMarkets, "Vaccine Market by Disease Type and Region," 2023.